Hodgkin lymphoma: must have received and failed frontline therapy
Mature B-Cell non-Hodgkin Lymphoma that is Relapsed/Refractory to standard therapy
NON-HODGKIN LYMPHOMA INCLUSION CRITERIA:
Patients with histologically/cytologically confirmed solid tumor, or lymphoma. For the expansion cohort, only patients with peripheral/cutaneous T cell lymphoma, Hodgkin's lymphoma, and other non-Hodgkin's lymphoma would be considered eligible
PHASE II: CD+ non-Hodgkin lymphoma (NHL) refractory or relapsed with no known curative therapies available
Patients must have histologically confirmed relapsed or refractory non-Hodgkin's lymphoma or Hodgkin's disease (World Health Organization [WHO] criteria) (Phase I)
At least  days have elapsed since bone marrow transplant and participant is off immune suppression for >=  weeks, if applicable; participants with ALL or non-Hodgkin lymphoma (NHL) who were transplanted in first remission are eligible for this study
Presence of measurable disease defined per the  International workshop on CLL guidelines, or by  Lugano criteria for non-Hodgkin lymphoma
Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) at high-risk of relapse or progression if not in remission:\r\n* Eligible patients with aggressive histologies (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell histologies) in CR.\r\n* Eligible patients with indolent B cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have nd or subsequent progression with stable disease/CR/partial remission (PR) with no single lesion equal to or more than  cm.\r\n* Eligible patients with HL will be without progression of disease (POD) after salvage chemotherapy with no single lesion equal to or more than  cm.
Indolent NHL or Hodgkin lymphoma with POD after most recent salvage chemotherapy.
Any B-cell non-Hodgkin lymphoma would be eligible for phase I portion of the study
Undergoing autologous stem cell transplant for one of the following diagnoses:\r\n* Multiple myeloma\r\n* Non-Hodgkin lymphoma
Hodgkin lymphoma  must have received and failed frontline therapy
Patients with histologically proven Hodgkin lymphoma (HL) will be eligible for transplantation after failing prior therapy
For NHL, detectable PET-positive disease according to the Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Active CNS involvement of non-Hodgkin lymphoma (NHL)
Eligible patients with Hodgkin lymphoma must fulfill one of the following criteria: ) have received two prior therapies, one of which must be an autologous stem cell transplant, or ) have received three prior lines of therapy; eligible patients with any of the listed peripheral T cell lymphomas or non-Hodgkin lymphomas must have received two lines of prior therapy, at least one of which must contain cytotoxic chemotherapy; patients with diffuse large B-cell lymphoma or primary mediastinal B-cell lymphoma must have received  prior treatment regimens at least  of which included an anthracycline and an anti-CD monoclonal antibody
Patients must have a histopathologically confirmed diagnosis of an aggressive B-cell non-Hodgkin lymphoma that is recurrent or refractory to standard therapy
Classic Hodgkin Lymphoma (cHL), relapsed or refractory
Patients must have histologically documented or cytologically confirmed Hodgkin lymphoma; confirmation must include CD expression
Must not have had second line chemotherapy for Hodgkin lymphoma
Patients must have histologically documented or cytologically confirmed Hodgkin lymphoma with CD expression
To be performed within  business days prior to day : Alanine aminotransferase (ALT) =<  x ULN unless demonstrated Hodgkin lymphoma involvement of the liver
There must be histological confirmation of relapse after alloSCT of any of the following diseases: any mature B cell lymphoma (classical Hodgkin lymphoma [cHL] or non-Hodgkin lymphoma [NHL]), acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Relapsed Hodgkin's disease or non-Hodgkin's lymphoma (NHL)
Hodgkin lymphoma:\r\n* Relapsed disease with progression after autologous bone marrow transplant or are ineligible for this procedure\r\n* Responding to therapy prior to enrollment
Non-Hodgkin lymphoma:\r\n* Responding to therapy prior to enrollment; \r\n* Progression after autologous bone marrow transplant or are ineligible for this procedure
PHASE I: Patients with relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma; patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are also eligible; in addition, patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least  prior therapies; patients with DLBCL and Hodgkin lymphoma (HL) will be eligible if there is no available standard therapy
Patients must have histologically documented or cytologically confirmed Hodgkin lymphoma with CD expression
Prior ibrutinib for Hodgkin lymphoma is not allowed
Large-cell lymphoma, Hodgkin lymphoma and multiple myeloma with chemotherapy sensitive disease who are ineligible for an autologous transplant
Previously untreated non-Hodgkin lymphoma or Hodgkin lymphoma; all stages of disease are allowed; also eligible are patients who have started or completed one or more cycles of treatment as part of a planned first line regimen, or those who have received local radiation or surgery or corticosteroids for disease control
Planned treatment with standard first line therapy for non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL)
Patients must have histologically confirmed transformed indolent B-cell non-Hodgkin lymphoma that is relapsed or refractory to at least one line of therapy
Relapsed or refractory lymphoid malignancies (including non-Hodgkin lymphoma, Hodgkin lymphoma and chronic lymphocytic leukemia) meeting the following criteria:\r\n* Disease status: stable disease, partial remission or nd and rd complete remission
Patients with non-Hodgkin lymphoma (NHL) other than DLBCL; including \transformed\ DLBCL
Patients with refractory B-cell or T-cell non-Hodgkin's lymphoma or Hodgkin's lymphoma who are eligible for allogeneic transplantation
Recipients of first/second ASCT for the treatment of hematologic malignancies (multiple myeloma, Hodgkin's and non Hodgkin's lymphoma)
Non-Hodgkin lymphoma with chemoresponsive disease in any of the following categories:\r\n* Intermediate or high grade lymphomas who have failed to achieve a first complete remission (CR) or have relapsed following a st remission who are not candidates for autologous transplants\r\n* Any non-Hodgkin lymphoma (NHL) in remission which is considered not curable with chemotherapy alone and not eligible/appropriate for autologous transplant
Non-Hodgkins lymphoma with chemoresponsive disease in any of the following categories: \r\n* Intermediate or high grade lymphomas who have failed to achieve a first CR or have relapsed following a st remission who are not candidates for autologous transplants\r\n* Any non-Hodgkin lymphoma (NHL) in remission which is considered not curable with chemotherapy alone and not eligible/appropriate for autologous transplant
Lymphoma: patients with \r\n* Diagnosis of non-Hodgkin lymphoma (NHL) or Hodgkin's lymphoma (HL), of any histological grade\r\n* Refractory or relapsed disease after standard chemotherapy\r\n* High risk of early relapse following autograft alone
Large-cell lymphoma, Hodgkin lymphoma and multiple myeloma with chemotherapy sensitive disease that has failed or patients who are ineligible for an autologous transplant
Non-Hodgkin's lymphomas in the following categories: mediastinal gray zone lymphoma and primary mediastinal B cell lymphoma
Histologically proven within the last  months of relapsed or refractory\r\n* Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) nodal or extranodal OR\r\n* Cutaneous T-cell lymphoma (CTCL) including mycosis fungoides (MF), as well as transformed MF OR\r\n* Breast adenocarcinoma with nodal or cutaneous metastases (stage )\r\n** NOTE: Patients must be refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for their condition\r\n** NOTE: The patient must not be a candidate for any curative therapy or any known life-prolonging therapy
Phase b only: B-cell non-Hodgkin's lymphoma (NHL), relapsed or refractory to standard approved therapies
Have had prior chemotherapy or radiotherapy for Hodgkin lymphoma
Non-Hodgkin lymphoma with poor risk features not suitable for autologous HCT
Patients must have histologically documented (confirmed at the Laboratory of Pathology, National Cancer Institute [NCI]), relapsed solid tumor malignancy or Hodgkin's disease/non-Hodgkin lymphoma that is metastatic or unresectable for which standard curative measures do not exist, or are associated with minimal patient survival benefit
Hodgkin and non-Hodgkin lymphoma (all types, including mantle cell lymphoma)\r\n* Primary treatment failure\r\n* Relapse after autologous stem cell transplant (SCT)\r\n* Non-CR after salvage regimen
Relapsed or refractory Hodgkin lymphoma following failure of standard frontline chemotherapy for the treatment of classical Hodgkin lymphoma
AIDS-related non-Hodgkin lymphoma and other non-Hodgkin lymphoma\r\n* Failed standard first-line therapy; and\r\n* Failed autologous stem cell transplant if indicated for histology (i.e diffuse large B-cell lymphoma) or autologous stem cell transplant is not feasible
Subjects with any previously treated advanced (metastatic or refractory) solid tumor type and B-cell non-Hodgkin lymphoma
Subjects must have a previously treated advanced solid tumor or B cell non-Hodgkin's lymphoma to be eligible
Phase I (Cohort T): Participants with non-Hodgkin's lymphoma, regardless of PIKCA mutation status
non-Hodgkin lymphoma
Pediatric solid tumor (including Hodgkin's and Non-Hodgkin's lymphoma), for which prior treatment had proven to be ineffective (that is, relapsed or refractory) or intolerable
Histologically confirmed diagnosis of a non-Hodgkin or Hodgkin lymphoma that has progressed in spite of prior treatment, and for which additional effective standard therapy is not available
Histological evidence of transformation of FL into high-grade B-cell non-Hodgkin's lymphoma (NHL)
Histologically confirmed B-cell non-Hodgkin's lymphoma that has relapsed after or failed to respond to at least one prior treatment regimen and for which no suitable therapy of curative intent or higher priority exists
Patients must have histologically confirmed CD positive relapsed or refractory Hodgkin lymphoma
Patient with Hodgkin's lymphoma with relapsed or refractory disease who are not eligible for stem cell transplantation or other standard therapies
Indolent / aggressive B-cell non-Hodgkin's lymphoma (NHL)
Hodgkin's lymphoma (HL)
Patients must have histologically confirmed relapsed or refractory mantle cell lymphoma or low grade B-cell non-Hodgkin lymphoma (NHL); patients with evidence of transformation to a high grade histology will not be eligible
Any patient, regardless of age or sex, with one or more of the following EBV-positive or associated disorders, regardless of the histological subtype:\r\n* Hodgkin lymphoma\r\n* Non-Hodgkin lymphoma\r\n* Lymphoproliferative disorder\r\n* Nasopharyngeal carcinoma\r\n* Leiomyosarcoma\r\n* Severe chronic active EBV infection syndrome (SCAEBV), defined as high EBV viral load in plasma or peripheral blood mononuclear cell (PBMC) (>  genomes per ug PBMC deoxyribonucleic acid [DNA]) and/or biopsy tissue positive for EBV
Any patients, regardless of age or sex, with one or more of the following EBV-positive or associated disorders, regardless of the histological subtype:\r\n* Hodgkin lymphoma\r\n* Non-Hodgkin lymphoma\r\n* Lymphoproliferative disorder\r\n* Nasopharyngeal carcinoma\r\n* Leiomyosarcoma\r\n* Severe chronic active EBV infection syndrome (SCAEBV), defined as high EBV viral load in plasma or PBMC (>  genomes per Mg PBMC DNA) and/or biopsy tissue positive EBV
Patients must have at least one bi-dimensionally measurable lesion (which has not been previously irradiated) according to the Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification.
Confirmed diagnosis of Hodgkin's Lymphoma
Phase I: Patients must have histologically confirmed relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma (World Health Organization [WHO] criteria), with no accepted curative options
Diagnosed or treated for malignancy other than indolent Non-Hodgkin lymphoma
Has received prior therapy for Hodgkin lymphoma, except as noted
Inclusion Criteria:\n\n         Aged  years or older, with lymphoid malignancies of B-cell origin as follows:\n\n        *Indolent / aggressive B-cell (NHL) Non- Hodgkin's Lymphoma:\n\n        EXCLUDING: Burkitt lymphoma and precursor B-lymphoblastic leukemia/lymphoma\n\n        INCLUDING: any non-Hodgkin's B-cell malignancy such as CLL and rare non-Hodgkin's B-cell\n        subtypes such as Hairy Cell Leukemia, Waldenstrom macroglobulinemia, Mantle cell lymphoma,\n        transformed NHL histologies, etc.\n\n        *Hodgkin's lymphoma\n\n          -  Life expectancy of  weeks or longer.\n\n          -  Subject must have received ?  prior treatment regimen.\n\n          -  The subject must not be a candidate for potentially curative therapy, including stem\n             cell transplant.\n\n        Exclusion Criteria:\n\n          -  Received an investigational study drug within  days or  half-lives (whichever is\n             longer) prior to receiving the first dose of study drug.\n\n          -  Received any approved anticancer medications within  days or  half-lives (whichever\n             is longer) prior to receiving their first dose of study drug ( days for\n             nitrosoureas) EXCEPT steroids at ?  mg prednisone daily (or equivalent).\n\n          -  Has any unresolved toxicity ? Grade  from previous anticancer therapy.\n\n          -  Has history of brain metastases or spinal cord compression, or lymphoma involving the\n             central nervous system.\n\n          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of ? .\n\n          -  Received allogeneic hematopoietic stem cell transplant within the last  months, or\n             has active graft versus host disease (GVHD) following allogeneic transplant, or is\n             currently receiving immunosuppressive therapy following allogeneic transplant.\n\n          -  Received autologous hematopoietic stem cell transplant within the last  months.\n\n          -  Laboratory parameters not within the protocol-defined range.\n\n          -  Current or recent history (< days prior to screening and/or < days prior to\n             dosing) of a clinically meaningful bacterial, fungal, parasitic or mycobacterial\n             infection.\n\n          -  Current clinically active viral infection.\n\n          -  Known history of infection with the human immunodeficiency virus (HIV).\n\n          -  History of active hepatitis or positive serology for hepatitis.
Non-Hodgkin's lymphoma (NHL): High risk subjects with responsive disease after first relapse. High risk includes those with Burkitt's Lymphoma and those with extensive marrow involvement at diagnosis-precluding autologous transplant.
Histologically confirmed relapsed or refractory Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL)
A concurrent diagnosis of systemic ALCL, or other non Hodgkin lymphoma (excluding LyP) or Sezary syndrome or B disease
Patients with non-Hodgkin lymphoma (NHL) other than MCL
Patients must have no evidence or history of non-Hodgkin lymphoma (NHL) outside of CNS
Patients must not have received prior chemotherapy or radiation therapy for the treatment of Hodgkin lymphoma
Hodgkin Lymphoma beyond first remission achieving at least a partial response to most recent therapy with no evidence of progression prior to transplant.
Non-Hodgkin Lymphoma beyond first remission achieving at least a partial response to most recent therapy with no evidence of progression prior to transplant.
For participants with follicular lymphoma: prior treatment for non-Hodgkin's lymphoma with chemotherapy, immunotherapy, or radiotherapy
Patients with histologically confirmed CD positive B-cell non-Hodgkin lymphoma (NHL) who are candidates for autologous stem cell transplantation (SCT)
Hodgkin lymphoma patients must have received at least  prior regimens and received, declined, or be ineligible for autologous transplant
Patient has histologically confirmed diagnosis of Hodgkin lymphoma
Previously treated or refractory large B-cell lymphomas, grey-zone lymphoma, Hodgkin lymphoma, including lymphocyte predominant Hodgkin lymphoma (LPHL)
Other non-Hodgkin lymphoma (NHL) histologies
Having \currently active\ second malignancy unrelated to Hodgkin lymphoma (HL) or NHL, unless they have completed anti-cancer therapy, are in complete response and are considered by their physicians to be at less than % risk of relapse
No evidence of systemic non-Hodgkin's lymphoma.
Tumor type criteria: relapsed/refractory non-Hodgkin's lymphoma (NHL) that meets one of the following criteria:
Have biopsy-confirmed non-Hodgkin lymphoma, of any type
Have evidence of progressive non-Hodgkin lymphoma
Patients with relapsed/refractory lymphoma (B cell non-Hodgkin) who have lack of objective response to at least two prior chemotherapy regimens
Clinical evidence of extra-central nervous system (CNS) (systemic) non-Hodgkin lymphoma
Plasma cell myeloma and Hodgkin lymphoma are excluded
Patient must have relapsed or refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease. Patients must have CNS  disease. Patient must have histologic verification of disease at original diagnosis. Patient must have measurable disease documented by clinical or radiographic criteria or bone marrow disease present at study entry.
Prior HSCT for Hodgkin's Lymphoma: Patients with Hodgkin's lymphoma must have had prior attempt at autologous HSCT.
Diagnosis of multiple myeloma or non-Hodgkin lymphoma
Diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma
Chronic lymphocytic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma are excluded
Histologically confirmed, previously untreated Hodgkin lymphoma
Non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) in nd or greater complete remission, partial remission
Patients must have histologically documented or cytologically confirmed Hodgkin lymphoma with CD  expression
Chemotherapy-sensitive relapsed lymphoma (complete or partial response), Hodgkin or non-Hodgkin lymphoma, no evidence of \bulky\ disease (>  cm in diameter)
Diagnosis of leukemia, non-Hodgkin's lymphoma, Hodgkin's disease or other hematologic malignancy.
Non-Hodgkin lymphoma (NHL)\r\n * Patients with NHL will be eligible if they fail to achieve a CR with initial chemotherapy or if they relapse following an autologous transplant\r\n * Patients who relapse following initial therapy, but are unable to undergo autologous transplantation, will also be eligible
T-cell non-Hodgkin's lymphoma (T-NHL) with one of the following: \r\n* Primary refractory (=< CR to st line or relapse within  months); or\r\n* Nonresponsive (SD/PD) to >=  line of salvage
Received >  line of therapy for Hodgkin lymphoma
Participants must have histologically or cytologically confirmed multiple myeloma, or non-Hodgkin lymphoma and must be undergoing melphalan conditioning for autologous HSCT
Large-cell lymphoma, Hodgkin lymphoma and multiple myeloma with chemotherapy sensitive disease that has failed or patients who are ineligible for an autologous transplant
Hodgkin and non-Hodgkin lymphoma: must have a complete or partial response with prior therapy
Diagnosis of recurrent Hodgkin's lymphoma (HL) with a treatment plan that will include high dose chemotherapy with/without total body irradiation and autologous cell transplantation
Hodgkin lymphoma  must have received and failed frontline therapy
Large-cell lymphoma, Hodgkin lymphoma and multiple myeloma with chemotherapy sensitive disease that has failed or patients who are ineligible for an autologous transplant
Any malignancy metastatic to other organ, excluding Hodgkins or non-Hodgkin's lymphoma
Lymphoma (including Hodgkin's)
History of histologically confirmed non-Hodgkin lymphoma (NHL) as assessed per medical record review
Clinically stable patients undergoing I- tositumomab (Bexxar) or Y- ibritumomab tiuxetan (Zevalin) for treatment of non-Hodgkin lymphoma
EBV-positive or KSHV-associated malignancy, including but not limited to:\r\n* EBV+ Hodgkin lymphoma\r\n* EBV+ non-Hodgkin lymphoma or lymphoproliferative disease\r\n* Primary effusion lymphoma\r\n* Kaposi's sarcoma\r\n* EBV+ gastric cancer\r\n* EBV+ nasopharyngeal cancer
Diagnosis of leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, or other hematologic malignancy.